Corbus Q1 net loss $23M, cash $138.2M; FDA alignment for CRB-701 registration path

Corbus Pharmaceuticals Holdings, Inc.

2026-Q1 EPS reported -$1.23

Net loss of $23.0M ($1.23 diluted LPS) vs $17.0M loss ($1.39 LPS) in Q1 2025.
Cash and investments $138.2M as of March 31, 2026, expected to fund operations into 2028.
Reached broad FDA alignment on registration path for CRB-701 in 2L HNSCC and cervical cancer; registrational study start expected summer 2026.
Updated CRB-701 data to be presented at ASCO 2026; CANYON-1 obesity study (n=240) fully enrolled, topline data summer 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Corbus Pharmaceuticals Holdings, Inc. reported first quarter ended March 31, 2026 results: net income net loss of approximately $23.0 million, EPS net loss per basic and diluted share of $1.23.

Period: first quarter ended March 31, 2026
Net income: net loss of approximately $23.0 million
EPS: net loss per basic and diluted share of $1.23
Result: reported results

Exact text from the filing

Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-218250

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.